Atara Biotherapeutics says tabelecleucel BLA resubmitted to FDA

Partner Pierre Fabre Pharmaceuticals resubmitted the biologics license application after feedback from a Type A meeting in April. Atara said it expects to provide a revised anticipated PDUFA date when available.